As you know, there was a negotiated outcome and then there was a change in some of those elements, including those related to biologic drugs. That obligation was removed from the agreement so Canada can continue to carry out its policy in that area.
There's nothing specifically related to cost as such, but if there's any provision that prevents the entry of generic versions of drugs, that would have a potential impact on drug costs in the future. With the removal of that provision, the only other change that needs to be made to Canada's regime is in respect of the patent term adjustment for delays in the processing of a patent application by a patent office.